Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability

Psoriasis (PsO) is a chronic, systemic, immune-mediated inflammatory skin disease affecting 1% to 5% population worldwide. In one-third of patients, the first symptoms of PsO manifest in childhood, with a mean age of nine years. Psoriasis in children under 16 years of age constitutes 4% of dermatolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Narbutt, Joanna, Niedźwiedź, Michał, Lesiak, Aleksandra, Ceryn, Justyna, Skibińska, Małgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940655/
https://www.ncbi.nlm.nih.gov/pubmed/36815128
http://dx.doi.org/10.2147/PPA.S350753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940655/
https://www.ncbi.nlm.nih.gov/pubmed/36815128
http://dx.doi.org/10.2147/PPA.S350753

Ejemplares similares